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SUMMARY
Chronic hepatitis C virus (HCV) infection has become a major health problem affecting an
estimated 170millionpeople worldwide. Theepidemiology ofHCV and its response to treatment
in Northern Ireland has not been described before.
Our aims were to determine the epidemiology, histological stage, suitability for treatment and
response to treatment in patients with hepatitis C presenting to one clinic in Northern Ireland.
All patients were prospectively recruited with hepatitis C attending the Liver Clinic, Royal
Victoria Hospital during the period December 1992 to June 1997.
Sixty patients (33 male, mean age 44 years, range 19-84 years) who tested anti-HCV antibody
positive were identified. The predominant genotypes were lb (33%), 3a (28%) and la (26%).
Mostpatients(78%)wereasymptomaticatthetimeofdetectionandonlyfour(7%)gaveahistory
ofjaundice. The most common modes oftransmission were i.v. drug use in 30 (50%) and blood
products in 20 (33%) patients. Forty-eight (86%) ofthe 56 patients tested were PCR positive for
HCV RNA. Fifty-one patients (85%) underwent liver biopsy ofwhom 13 had cirrhosis (22% of
original group). Twenty-nine patients were suitable for treatment, but three declined treatment
and only 26 (43%) started interferon-alpha. During treatment 17 (65%) patients became PCR
negative and eight (31%) remained PCR negative 12 months after completion oftherapy. Liver
histology wasassessedbefore andafterinterferontreatmentin 17patientsandshowednochange
in total necroinflammatory scores (p=0.1) or staging of architectural change (p=0.55).
Conclusions: The epidemiology and response to therapy of HCV in Northern Ireland appear
comparable to elsewhere in the UK. Only a minority of anti-HCV positive non-haemophiliac
patientsprogresstohaveinterferontherapysuggestingthatthecostoftreatingchronicHCVmay
not be as great as initially thought.
INTRODUCTION
The hepatitis C virus (HCV) results in chronic
hepatitis C (CHC) in up to 85% ofthose acutely
infected.1 Chronic HCV infection has become a
majorhealthissuethroughouttheworld affecting
anestimated 170 millionpeople.2Up to onethird
of those with CHC will develop cirrhosis, and
end-stage liver disease due to CHC is now the
leading indication for liver transplantation
worldwide.3 The goal of therapy is obviously to
prevent progression to end-stage liver disease
with its consequences. Monotherapy with
interferon alpha was the mainstay of treatment
for CHC from the virus was first identified in
1989 until the late 1990's. Given the scale ofthe
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HCV problem, the cost of treating most HCV
patients ispotentially enormous. Howevernotall
chronic HCV patients may be suitable for
treatment and some have fairly indolent disease
that does not require therapy.
Despite over a decade of experience with HCV,
debate continues regarding whom to treat and
how. Studieshaveshownthatanumberoffactors
can influence response to therapy such as viral
loadandviralgenotype.4TherearesixmainHCV
genotypes and genotype 1 is associated with a
worse response to interferon therapy. The
prevalence of genotype 1 varies throughout the
world and its prevalence in Northern Ireland is
unknown. Northern Ireland is thought to have a
lower incidence of i.v. drug abuse (one of the
main riskfactors forHCV) than elsewhere in the
UnitedKingdombuttheepidemiologyofHCVin
Northern Ireland has not previously been
described. Variations infactors such as genotype
prevalencecouldtranslateintodifferenttreatment
response rates in Northern Ireland compared to
elsewhere.
Chronic HCV patients were first treated with
interferoninNorthernIrelandin 1992andpatients
weretreatedwiththesamemonotherapyprotocol
until 1997 when the NIH Consensus Statement
on Management of Hepatitis C was published
leading to a change in treatment protocols.6 The
aimsofthisstudyweretwofold: Toprospectively
recruit all non-haemophiliac chronic HCV
patientspresentingtothelargesthepatologyclinic
in Northern Ireland from 1992 until 1997 and to
describetheirdemographicdetails; andsecondly,
using clearly defined criteria, to determine the
proportionofsuchpatientswhorequiredtreatment
andtodescribetheirhistologicalandbiochemical
responses.
PATIENTS AND METHODS
All non-haemophiliac patients attending the
HepatologyClinicattheRoyalVictoriaHospital,
Belfast who were found to be anti-HCV positive
during the period December 1992 to June 1997
were prospectively recruited. Preliminary
assessment involved blood testing for liver
biochemistry, anti-HCV antibody, HCV RNA
testing by polymerase chain reaction (PCR) and
HCV genotyping. Liverbiopsy was offered to all
patients who had a positive PCR for HCV-RNA
or had abnormal LFTs. Patients who were PCR
positive for HCV-RNA who had evidence of
interface or intralobular hepatitis or cirrhosis on
liver biopsy and were medically fit to undergo
treatment were offered interferon alpha therapy.
Thosepatientswhohaddecompensatedcirrhosis,
human immunodeficiency virus (HIV) infection,
severe co-morbidity, pregnancy, continued
intravenous drug abuse, other causes of chronic
liver disease or who were PCR negative were
excluded from treatment.
Interferonalpha2awasgivenas astartingdoseof
3 million units (MU) subcutaneously thrice
weekly for 1 month, then4 MU thrice weekly for
1 month and finally up to 5 MU thrice weekly for
6 months with monthlymonitoringofLFTs, FBP
andHCV-RNA PCR. Patients whohaddifficulty
with side-effects or a low platelet count due to
interferon were maintained for 6 months on the
maximum dose tolerated.
On completion of therapy, LFTs and PCR were
monitored every 3 months in those who had
become PCR negative during treatment and a
repeat liver biopsy was offered. Biopsies were
independently scored by two pathologists who
were blinded to the timing of each biopsy with
relationto treatment. Each biopsy was scoredfor
necroinflammation (0-18) and fibrosis (0-6) in
accordance with the previously published
modified Knodell Histology Activity Index for
grading and staging ofchronic hepatitis (Ishaket
al, J Hepatol, 1995).
Treatment response was defined as clearance of
virus from the blood (PCR negative) and
normalisation of ALT at completion of therapy
and sustained viral response as the maintenance
of this response at 6 months after completion of
therapy.7
RESULTS
Sixty patients were recruited (33 male, mean age
44 years, age range 19-84 years). The most
commongenotypes were lb (33%), 3a(28%) and
la (26%). Mostpatients (47 (78%)) had minimal
symptoms related to liver disease and were
detectedbyscreening (including 12whoattended
a genitourinary clinic, 12 who had screening of
abnormal LFTs, six detected by the Blood
Transfusion service, three detected by the Blood
Transfusion Lookback exercise, nine who were
screened because they had previous risk factors
andfive who were testedby theirGP on aroutine
visit). Only four(7%) patients gave ahistory ofa
previous illness with jaundice. The modes of
transmission of HCV were i.v. drug use in 30
C) The Ulster Medical Society, 2004.
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Fig 1. Mode of transmission of HCV in 60 non-
haemophiliac anti-HCV positive patients.
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(50%), blood products in 20 (33%), sexual
contacts in four (7%) and unknown in six (10%)
patients (Figure 1).
Forty-eight (86%) of the 56 patients tested by
PCR were positive for HCVRNA (80% of the
original group, withfourpatientsfailingtoattend
for PCR testing). Blood investigations revealed
abnormalliverbiochemistry (elevatedAST,ALT
or GGT) in 72% ofthe cohort. Liver biopsy was
performed in 51 (85%) patients and revealed
cirrhosis in 13 (22% ofthe original group, Figure
2). Alcoholmayhavebeen afactorin threeofthe
13cirrhoticpatients. Twopatients(3%)developed
a hepatoma during follow-up: one patient was
cirrhotic at presentation, became PCR negative
with interferon therapy but relapsed on stopping
treatment and died four years after presentation
(aged48 yrs); the otherpatient was also cirrhotic
at presentation, failed to respond to interferon
therapy anddiedone yearafterpresentation aged
72.
Figure 3 shows the outcome of the 60 patients
studied with respect to whether or not they
received interferon treatment. Twelve patients
were excluded as they were PCR negative. Five
patientswhowereHCV-RNAPCRpositivefailed
to attend for follow-up assessment and a further
three patients underwent full assessment but
declined the offeroftreatment. Fourteenpatients
who were HCV-RNA PCR positive were not
offered treatment due to the fact that they were
either not medically fit to undergo treatment (6)
or were deemed to have minimal disease activity
Fig 2. Resultsofliverhistologyfor60non-haemophiliac
anti-HCV positive patients.
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(8) based on LFTs and liver histology. This left
26patients (43%) whowereofferedandaccepted
interferon therapy. Twopatients (8%) developed
thyroid dysfunction (one thyrotoxic, one
hypothyroid) during interferon therapy.
Seventeen (65%) patients became HCV-RNA
negative during therapy and nine remained
positive (including one patient who only had 2
days oftherapy, one who defaulted afterjust one
month ofinterferon and four who were unable to
achieveasatisfactoryinterferondoseorlengthof
therapy dueto sideeffects). Eight (31%) patients
had a sustained response, remaining HCVRNA
negativeatleast 12monthsafterstoppingtherapy,
eight became HCVRNA positive again and one
patient became HCVRNA negative but failed to
attend for follow-up (Figure 3). Age, sex,
genotype, presence of cirrhosis or mode of
transmissiondidnotsignificantlyaffecttreatment
success.
The Table shows the results ofliver histology in
17 patients before and after interferon therapy
(including three who failed to become PCR
negative). The overall total scores showed no
significantimprovementwithtreatmentforeither
grading of necroinflammatory scores (p=O.1) or
staging of architectural change, fibrosis and
cirrhosis (p=0.55). Assessment of the four
separatecomponentsofgradingshowedthatthere
was a significant improvement in the score for
focal lytic necrosis, apoptosis and focal
inflammation (p=0.01) but no significantchange
in the scores for piecemeal necrosis, confluent
necrosis or portal inflammation.
© The Ulster Medical Society, 2004.
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Fig 3. Outcome of 60 ant-HCV positive non-haemophiliac patients showing HCVRNA PCR status and outcome of
interferon therapy.
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TABLE
Histological scoresfor grading and staging ofchronic hepatitis in 17patients before and after
treatment ofchronic HCVwith interferon alpha (Modified Knodell Histology Activity Index)
Before Treatment After Treatment
Grade (O - 18) Stage (O - 6) Grade (O - 18) Stage (O - 6)
P1 7 3 3 3
P2 7 3 5 3
P3 10 5 9 6
P4 8 5 4 6
P5 7 5 11 5
P6 7 5 7 5
P7 6 3 5 2
P8 6 5 6 5
P9 5 4 3 2
PlO 6 1 1 1
P11 4 3 4 3
P12 4 2 2 1
P13 6 3 3 3
P14 8 5 16 6
P15 6 3 4 2
P16 8 3 4 3
P17 5 3 5 3
Overall 6(5.5-7.5) 3(3-5) 4(3-6.5) 3(2-5)
Median (IQR) p = 0.1 p = 0.55
DISCUSSION
EstimatessuggestthathepatitisCcurrentlyaffects
200,000to400,000peopleintheUK,themajority
ofwhomhave chronic HCV infection.8 The most
important route for transmission of HCV is
parenteral andthemajorityofthose infectedgive
a history of either intravenous drug abuse or
receipt of blood/blood products prior to 1991
whenscreeningofbloodforHCVwasintroduced.
Much less commonly, infection can be due to
sexualcontact,verticaltransmissionornon-sexual
householdcontact. Asmallproportionofpatients
have no identifiable risk factors.
Not all patients with chronic HCV infection
develop severe liverdisease but 20-30% go on to
develop cirrhosis after a mean of30 years andup
to4% ofcirrhotic HCVpatients peryeardevelop
a hepatoma.6 Several factors are associated with
increasedriskofdiseaseprogression: age over40
at time of infection, male sex, excess alcohol,
high viral load, immune deficiency, coinfection
with HIV or hepatitis B and genotype 1. Six
genotypes and numerous subtypes ofHCV have
been identified. Genotypes la and lb are by far
the most common in the Western world,
accounting for up to 70% of cases in the USA.9
This figure is thought to be closer to 50% in the
UK but there are no comprehensive data.
Perhaps not surprisingly, the epidemiology of
chronic HCV in Northern Ireland (based on our
studysample)isinkeepingwiththedatadescribed
above. Allowances should be made for the fact
that our study group excluded haemophiliac
patients who mostly acquired HCV from blood
products. Genotypes la and lb accounted for
57% of those whose genotype was tested and iv
drug abuse was the most common risk factor
accountingforhalfofthestudygroup.Asexpected
C The Ulster Medical Society, 2004.
2930 The Ulster Medical Journal
fromotherdata, 1 in 10peoplehadnoidentifiable
risk factor forHCV. The fact that at least 22% of
the study group had cirrhosis at the time of
presentation is probably in keeping with the
widely quoted figure of20-30% ofchronic HCV
patients developing cirrhosis within 20 years.1
This relatively high figure demonstrates the
insidiously progressive nature of chronic HCV
infection that can present many years after
infection with advanced disease. Unfortunately
we were unable to determine the length of time
frominitial HCV infectionuntilpresentation and
therefore cannotcommentonthemeantimeuntil
development of cirrhosis.
The similarity between our study group
demographics and other UK data 1 does not
suggest that there should be any significant
differences in response to treatment and the data
bear this out. The initial response to interferon
monotherapy treatment (61%) and subsequent
sustainedresponserate (31%)bothcomparevery
favourably with the generally quoted initial
responseandsustainedresponseratesof47% and
20% respectively.1 The slightly betterfigures we
obtained shouldnotbe over-interpreted, because
of the small sample size. However it could be
suggested that the slightly higher response rate
was due to higher doses of interferon used (5
million units thrice weekly rather than the more
commonly used 3 million units thrice weekly).
Liver histology data showed an improvement
following therapy in some of the inflammatory
parameters. Presumably if numbers had been
largeritwouldhavebeenpossibletodemonstrate
a significant improvement in overall histology
scores of necroinflanimation and liver
architecture.
ThetreatmentdatafortheNorthernIrelandcohort
helps to illustrate one very important point
regarding the number of patients treated. Given
the prevalence of chronic HCV infection
worldwide and the cost of treatment with
interferon, the potential cost of treating the
problem might seem prohibitive. Yet this study
has shown that a minority of non-haemophiliac
patientswithprevious HCVinfectionwhopresent
to a hospital clinic actually proceed to have
interferon therapy (Figure 3). A combination of
factors such as minimal evidence of disease
progression, unsuitability for interferon therapy
and failure to comply with medical advice and
follow-up resulted in only 43% of our group
starting treatment. Failure to comply was one of
the most important factors accounting for almost
1 in 5 ofthose who had chronic HCV. Anecdotal
evidence from many centres confirms that poor
compliance is often a problem with non-
haemophiliac chronic HCV patients partly dueto
the large proportion who are previous or current
i.v. drug abusers. One study showedthatas many
as 42% ofpatients who underwent investigation
ofchronicHCVinfectiondidnotwanttoproceed
with treatment.10
In summary, based on a cohort of 60 non-
haemophiliac patients the epidemiology ofHCV
infection in Northern Ireland appears to be very
comparable to elsewhere in the UK. The most
common risk factor is iv drug abuse followed by
contact with blood products and over half of
patients aregenotype laor lb. Only aminorityof
patients actually receives treatment andresponse
rates with interferon monotherapy compare
favourably with elsewhere.
The last patient was recruited to this study in
1997 and since then there have been dramatic
advances in the treatment of chronic HCV
infection. Combination therapy (interferon plus
oral ribavirin) has been introduced and more
recently the use of pegylated interferon has
improvedresponserates. Thelength oftreatment
is now tailored to match the specific hepatitis C
genotype. In January 2004, NICE produced
updated guidelines stating that combination
therapy with pegylated interferon alpha and oral
ribavirinisnowthetreatmentofchoiceforpatients
with chronic HCV infection.'1 Studies have
demonstratedthatsustainedresponserates of76-
82% are now achievable for genotypes two and
three.'2' 13 The response rates in Northern Ireland
to newer therapeutic strategies are yet to be
determined.
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